News

Researchers Share Story of Patient Who Inspired Them

Researchers in Hong Kong have shared a case report about how they were inspired and humbled by a teenage girl with spinal muscular atrophy (SMA) who got through a difficult hospital stay while maintaining a hopeful spirit and never losing sight of her goals. “Although the life of children…

Spinraza Most Effective in Younger Type 1 Children: Real-world Study

In a real-world study involving more than 40 Swiss patients with spinal muscular atrophy (SMA), Spinraza (nusinersen) was found to effectively improve motor function — particularly among younger children with SMA type 1. Older treated patients gained or stabilized their motor function, but infections prompted the need for ventilation and…

Novartis Boosts Zolgensma Production Capacity After FDA Clearance

Novartis Gene Therapies is expanding its manufacturing capacity for Zolgensma (onasemnogene abeparvovec) — its disease-modifying gene therapy for spinal muscular atrophy (SMA) — after its commercial licensure approval was approved by the U.S. Food and Drug Administration (FDA). The approval will allow the company to produce, test and…